Bio & Pharma
GC Biopharma's Sanfilippo treatment eligible for FDA priority review
The S.Korean company is entitled to request a shorter review period for the new drug's approval
By Jan 18, 2023 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![GC Biopharma headquarters](https://www.kedglobal.com/data/ked/image/2023/01/18/ked202301180041.700x.0.jpg)
GC Biopharma Corp. said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture specializing in orphan drugs, has received rare pediatric disease designation (RPDD) from the US Food and Drug Administration.
This disease is a genetic defect that causes progressive damage due to the accumulation of heparan sulfate in the central nervous system. It is a severe disease with most patients dying at the age of 15 as there is no approved treatment yet.
The two companies have developed enzyme replacement therapy (ERT)-based treatments since 2020, in which enzymes are injected into patients with enzyme deficiency.
According to the company's explanation, once it receives the RPDD designation from the FDA, it can apply for a "priority review voucher," which is the eligibility to shorten the new drug approval review period to six months.
"Based on the know-how we have gained in the field of orphan drugs, we will continue our efforts to provide better treatment options to patients suffering from rare diseases," a GC Biopharma official said.
Write to Jung-Eun Kim at likesmile@hankyung.com
More to Read
-
Bio & PharmaGC Biopharma confirms safety of flu vaccine in phase 1 trial
Dec 15, 2022 (Gmt+09:00)
1 Min read -
Green Cross' two Kosdaq-listed cell therapy arms to merge
Jul 18, 2021 (Gmt+09:00)
2 Min read -
COVID-19Green Cross in talks with Russia to produce COVID-19 vaccine
Mar 18, 2021 (Gmt+09:00)
3 Min read
Comment 0
LOG IN